News

EU Approval – Misoprostol Tablet for Induction of Labour

AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care

Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment

Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France

Er-Kim and AFYX Therapeutics A/S announce distribution and sales collaboration

Danish biopharmaceutical leader AFYX Therapeutics A/S secures DKK 25 million in Funding

Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration

PRESS RELEASE Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX’s induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will...

Interim Financial Report Q4 2024

PRESS RELEASE In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers...

Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France

PRESS RELEASE Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France. Hørsholm, Denmark January 13th 2025 - AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing...